# Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease

> **NCT03157037** · PHASE2 · COMPLETED · sponsor: **Mårten Segelmark** · enrollment: 15 (actual)

## Conditions studied

- Anti-Glomerular Basement Membrane Antibody Disease

## Interventions

- **BIOLOGICAL:** Imlifidase

## Key facts

- **NCT ID:** NCT03157037
- **Lead sponsor:** Mårten Segelmark
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-16
- **Primary completion:** 2020-07-24
- **Final completion:** 2020-07-24
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03157037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03157037, "Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03157037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*